First-Line Treatment Options for CLL
نویسندگان
چکیده
منابع مشابه
Chronic lymphocytic leukemia (CLL): first-line treatment.
For the past ten years, there has been a dynamic development of new therapeutic compounds and prognostic parameters for chronic lymphocytic leukemia (CLL). Hematologists and oncologists are challenged to use these new possibilities for an optimized, risk- and fitness-adapted treatment strategy, with the goal of achieving long-term remissions and preserving a good quality of life. This review is...
متن کاملRilpivirine and complera: new first-line treatment options.
Two antiretroviral medicines recently came on the scene for people starting HIV treatment for the first time: Rilpivirine (brand name Edurant) won marketing approval in May, and the following August saw approval of Complera, a single-pill once-daily regimen that joins rilpivirine with two other drugs. This article explains the science behind rilpivirine and Complera and how these drugs measure ...
متن کاملChronic Lymphocytic Leukemia (CLL): Upfront Treatment Options in 2017
Submit Manuscript | http://medcraveonline.com Abbreviations: CLL: Chronic Lymphocytic Leukemia; FCR: Fludarabine, Cyclophosphamide and Rituximab; PI3K: Phosphatidylinositol 3-kinase; IWCLL: International Workshop on Chronic Lymphocytic Leukemia; CIRS: Cumulative Illness Rating Scale; CIT: chemoimmunotherapy; FISH: Fluorescence In Situ Hybridization; PFS: Progression Free Survival; EMA: European...
متن کاملFirst-line treatment for hypertension
Published online 28 November 2001. Recent guidelines for hypertension management differ in their recommendations for routine firstline treatment for hypertension, as have previous generations of guidelines. For example, the United States JNC VI and British Hypertension Society guidelines both recommend low-dose diuretics and beta-blockers as first-line treatment unless there are compelling cont...
متن کاملFirst-line treatment for advanced pancreatic cancer.
Metastatic pancreatic cancer is a rapidly fatal disease with few therapeutic options. The authors summarize four abstracts (#148, #233, #158, #291) presented at the 2013 ASCO Gastrointestinal Cancers Symposium which were focused on novel agents for metastatic pancreatic cancer.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2017
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000527164.52463.9e